help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 2, 175-185, February 2007; doi:10.1634/theoncologist.12-2-175
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Management of Gastroesophageal Tumors
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gee, D. W.
Right arrow Articles by Rattner, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gee, D. W.
Right arrow Articles by Rattner, D. W.

Gastrointestinal Cancer

Management of Gastroesophageal Tumors

Denise W. Gee, David W. Rattner

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Key Words. Esophageal carcinoma • Gastric carcinoma • Esophagogastrectomy • Neoadjuvant therapy • Adjuvant therapy

Correspondence: David W. Rattner, M.D., Division of General and Gastrointestinal Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-1893; Fax: 617-724-0355; e-mail: drattner{at}partners.org

The incidence of adenocarcinomas of the gastroesophageal junction has increased in recent years. These tumors possess distinct pathophysiologic characteristics. Although the consensus is that an R0 resection (complete microscopic and macroscopic resection) is the goal when operating for curative intent, much controversy remains regarding other aspects of patient management. There is lack of consensus regarding the type of surgery to perform, the role and extent of lymphadenectomy, and the role of neoadjuvant therapy. Utilizing an evidence-based approach, this review article provides an overview of the management of gastroesophageal junction carcinomas with particular emphasis on current areas of controversy.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2007 by AlphaMed Press.